Go with the Flow-Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009.
acute lymphoblastic leukemia
blast cell clearance
children
flow cytometry
minimal or measurable residual disease
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Oct 2022
30 Oct 2022
Historique:
received:
18
08
2022
revised:
25
10
2022
accepted:
28
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Measurable residual disease (MRD) is a well-known tool for the evaluation of the early response to treatment in patients with acute lymphoblastic leukemia (ALL). In respect to predicting the relapse the most informative cut-off and time point of MRD measurement during therapy were evaluated in our study. Between 1 January 2013 and 31 December 2019, multiparametric flow cytometry (MFC) MRD was measured in the bone marrow of 140 children with ALL treated according to the ALL IC-BFM2009 protocol. The MRD cut-off of 0.1% and day 33, end of induction, were the most discriminatory for all patients. Patients with negative MRD on day 15 and 33 had a higher 5-year overall survival-OS (100%) and a higher relapse-free survival-RFS rate (97.6%) than those with positive levels of MRD (≥0.01%) at both time points (77.8% and 55.6%,
Identifiants
pubmed: 36358778
pii: cancers14215359
doi: 10.3390/cancers14215359
pmc: PMC9653819
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2018 Jan 1;36(1):34-43
pubmed: 29131699
Lancet. 1998 Feb 21;351(9102):550-4
pubmed: 9492773
Leukemia. 2010 Feb;24(2):345-54
pubmed: 20010622
Blood. 2010 Apr 22;115(16):3206-14
pubmed: 20154213
Curr Hematol Malig Rep. 2018 Dec;13(6):455-466
pubmed: 30446941
J Pediatr. 2018 Dec;203:14-24.e2
pubmed: 30213460
Leukemia. 2017 Feb;31(2):333-339
pubmed: 27560110
Przegl Lek. 2010;67(6):361-5
pubmed: 21344762
Int J Mol Sci. 2020 Feb 05;21(3):
pubmed: 32033444
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Blood. 2017 Apr 6;129(14):1913-1918
pubmed: 28167658
J Clin Oncol. 2014 Jan 20;32(3):174-84
pubmed: 24344215
Lancet. 1998 Nov 28;352(9142):1731-8
pubmed: 9848348
Lancet Oncol. 2013 Mar;14(3):199-209
pubmed: 23395119
J Clin Oncol. 2018 Jan 20;36(3):244-253
pubmed: 29148893
Blood. 2020 Apr 23;135(17):1458-1466
pubmed: 32027741
Lancet Oncol. 2014 Jul;15(8):809-18
pubmed: 24924991
Blood. 2008 Jun 15;111(12):5477-85
pubmed: 18388178
J Clin Oncol. 2009 Nov 1;27(31):5168-74
pubmed: 19805690
Int J Hematol. 2021 Apr;113(4):547-555
pubmed: 33386596
Blood. 2018 Mar 22;131(12):1350-1359
pubmed: 29284596
Blood. 2006 Jul 1;108(1):97-102
pubmed: 16537802
Blood. 2020 Jan 23;135(4):252-260
pubmed: 31821407
Blood Cancer Discov. 2021 Jul;2(4):326-337
pubmed: 34250504
Leukemia. 2009 Mar;23(3):528-34
pubmed: 19020543
JAMA Oncol. 2017 Jul 13;3(7):e170580
pubmed: 28494052
Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69
pubmed: 23757107
Pediatr Blood Cancer. 2019 May;66(5):e27590
pubmed: 30561169
Folia Med (Plovdiv). 2016 Mar 1;58(1):28-35
pubmed: 27383875
J Clin Oncol. 2012 Jul 1;30(19):2384-92
pubmed: 22614971
Blood. 2009 Apr 30;113(18):4153-62
pubmed: 19141862
Cancers (Basel). 2021 Apr 13;13(8):
pubmed: 33924381
Am J Hematol. 2019 Feb;94(2):257-265
pubmed: 30394566
J Clin Oncol. 2017 Feb 20;35(6):660-667
pubmed: 28045622
Cytometry B Clin Cytom. 2010 May;78(3):147-53
pubmed: 20201055
Blood. 2020 Apr 23;135(17):1414-1415
pubmed: 32324869